Jazz Pharmaceuticals (JAZZ) on Monday reported long-term survival results from a phase 2 trial evaluating its investigational HER2-targeted therapy Ziihera in combination with chemotherapy as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
The company said median overall survival reached 36.5 months among the 46 enrolled patients, with a median progression-free survival of 12.5 months. In the subgroup of 41 patients with centrally confirmed HER2-positive tumors, median progression-free survival was 15.2 months.
The data was presented at the American Society of Clinical Oncology annual meeting.
A Phase 3 trial evaluating Ziihera in the same indication is ongoing, with top-line results expected in the second half of 2025, Jazz said.
Price: 108.84, Change: +0.77, Percent Change: +0.71
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。